PolyU has a robust research community in Chinese Medicine. PolyU’s Research Centre for Chinese Medicine Innovation (RCMI) and Increasepharm (HK) Limited announced the establishment of the PolyU-Increasepharm Joint Research Laboratory for New Drug Development. With the generous support of HK$10 million from Increasepharm (HK) Limited, the joint lab will develop CM-based new drug for the coming 5 years to treat osteoporosis, sarcopenia, dementia, and ocular diseases.
The Signing Ceremony was held via hybrid mode on PolyU campus and broadcast live online, marking the official launch of the joint lab and research collaboration. Prof. Christopher Chao, Vice President (Research and Innovation), and Dr Angela Kung, Managing Director of Increasepharm (HK) Limited, signed the collaborative agreement under the witness of Professor Wing-tak Wong, Deputy President and Provost, Prof. Wong Kwok Yin, Vice President (Education), Prof. Chen Qingyan, Director of PolyU Academy for Interdisciplinary Research (PAIR), Prof. Raymond Wong, Dean of Faculty of Applied Science and Textiles, Prof. Larry Chow, Director of Research, Innovation Office, Prof. Wong Man Sau, Director of Research Centre for Chinese Medicine Innovation (RCMI), Dr Jessica Yu, Researcher of Increasepharm (HK) Limited and Prof. Zhang Baoxian, Chairman of Beijing Increasepharm Corporation Limited, Mr Zhang Hongwu, President of Beijing Increasepharm Corporation Limited, Prof. Zhou Yisheng, General Manager of Increasepharm (Hengqin) Institute Co., Ltd. ,and Dr. Hu Jing, Chief Scientist of Increasepharm (HK) Limited.
Through the close collaboration with Increasepharm, it is hoped to seize the strategic opportunities to integrate with the country’s overall development, further advanced drug discovery and development in view of the surging demand in healthcare and pharmaceutical industry.
About Research Centre for Chinese Medicine Innovation (RCMI)
RCMI was established in October 2021 as a university-level platform to facilitate impactful interdisciplinary research at PolyU. With over 40 faculty members from 7 departments with interdisciplinary expertise, RCMI aims to conduct high impact research to provide scientific evidence to elucidate traditional Chinese Medicine (TCM) theory for better understanding by the research community, medical community and the general public.
For more information, please go to https://www.polyu.edu.hk/rcmi
Beijing Increasepharm Corporation Limited is a new drug R&D institution integrating R&D design, pilot test incubation and achievement transformation with more than 20 years of experience. Itis a segmentation enterprise of Traditional Chinese Medicine (TCM) with the R&D whole process. The company has five major business sections, including TCM, chemical medicine innovation, clinical service, pilot-scale production and international business; it has established four R&D centers for traditional Chinese medicine dispensing granules, new Chinese medicine, Chinese classical formulas and consistency evaluation for generic drug, and built several new preparation technology platforms.
The way forward
The signature event of the year, Botanical Symposium, will be held on 2 December 2022 in hybrid mode which aims to bring together renowned researchers and scientists from PolyU, mainland and overseas to share research insights and explore innovative approaches of Chinese Medicine, from bench to bedside.
Stay tuned for further updates on RCMI website!